After the news broke yesterday that Novartis was to cut a slew of workers from its gene and cell therapy programs, this has left many wondering about its broader pacts in this space–and their future. GenVec, which is developing a hearing loss gene therapy with the Swiss major, was quick to say it will not be one of those axed.
In a brief statement released after the news broke about Novartis’ plans, GenVec filed a SEC form 8-K explaining: “On August 31, 2016, press reports disclosed that Novartis is planning to eliminate its internal unit dedicated to cell and gene therapy and redeploy most of the affected employees.
“Novartis is developing CGF166, GenVec’s lead product candidate for hearing loss, under a Research Collaboration and License Agreement between the two parties. Novartis has informed GenVec that it remains engaged on the CGF166 program and that Novartis’s internal changes are not expected or intended to reduce its support for the program.”
Novartis confirmed this week that it plans to cut its internal unit dedicated to cell and gene therapy. It will redeploy most of the 400 employees from these units, but said about 120 will be cut, according to press reports.
The fact that the GenVec deal remains in place, for now, will be some much needed good news for the biotech, which faces being delisted from the Nasdaq after remaining encamped in penny-stock territory.
Gaithersburg, MD-based GenVec signed a deal worth up to $213 million with Novartis back in 2010 with a focus on CGF166. Its drug was created via the AdenoVerse technology platform that is designed to use genes to treat or stop certain diseases.
The FDA lifted a planned clinical hold on its Phase I/II development in July after an independent body said it was safe for the study to continue. It currently had 9 enrolled patients.
Perhaps prompted by concerns over a potential cutting of the deal, GenVec was down by more than 7% yesterday to 53 cents a share. Novartis, meanwhile, was slightly down by 0.7% at end of play.
By Ben Adams
Source: Fierce Biotech
A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.
Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.
Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”